Clinical Trials Results - National Cancer Institute

Skip to content

National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?


	1-800-4-CANCER

	LiveHelp® online chat

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -6 of 6 Show results per page	View Search Criteria \| Help With Results


Sort By:	Version:	Format:

Last Modified: 1/14/2009 First Published: 8/24/2003


1.		Phase II Study of Sulindac and Tamoxifen in Patients With Desmoid Tumor That is Recurrent or Not Amenable to Standard Therapy

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and under at original diagnosis				NCI				COG-ARST0321 NCT00068419, ARST0321


2.		Influence of Sulindac and Probiotics on the Development of Pouch Adenomas in Patients With Familial Adenomatous Polyposis

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Prevention				Active				16 and over				Other				23266 KUN 2003-2911, NCT00319007

Last Modified: 12/3/2008 First Published: 8/18/2006


3.		Phase II Randomized Chemoprevention Study of Sulindac in Current or Former Smokers With Bronchial Dysplasia

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Biomarker/Laboratory analysis, Prevention				Active				40 to 79				NCI				MAYO-03-1-02 MAY03-1-02, NCT00368927


4.		Bevacizumab/Tarceva and Tarceva/Sulindac in Squamous Cell Carcinoma of the Head and Neck

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				Other				06-111 NCT00392665

Last Modified: 9/24/2008 First Published: 9/12/2008


5.		Phase II Study of Sulindac And Epirubicin Hydrochloride in Patients With Metastatic Malignant Melanoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Biomarker/Laboratory analysis, Treatment				Active				Over 18				Other				ICORG-06-03 ICORG 06-03 Epi Sulindac, EUDRACT-2006-006051-12, EU-20876, NCT00755976


6.		A Randomized Study of Sulindac in Oral Premalignant Lesions

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	No phase specified				Prevention				Active				Over 18				Other				04-099 NCT00299195

Select All on One Page

| | | | | | | |

A Service of the National Cancer Institute